Vanguard Capital Management
SANA icon

Vanguard Capital Management’s Sana Biotechnology SANA Stock Holding History

Vanguard Capital Management’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
8,375,421
+940,697
+13% +$3.03M ﹤0.01% 2236
2026
Q1 		$21.4M Buy
+7,434,724
New +$29.3M ﹤0.01% 2302

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's SANA Position: Q2 2026 in Review

Vanguard Capital Management increased its Sana Biotechnology (SANA) stake by 13% in Q2 2026, buying an estimated $3.03M and bringing the position to 8,375,421 shares worth $29.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2236.

Vanguard Capital Management first reported a position in SANA in Q1 2026 and has held it in 2 quarters since. 208 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Vanguard Capital Management held 8,375,421 shares of Sana Biotechnology worth $29.2M as of Q2 2026.
  • Vanguard Capital Management bought 940,697 Sana Biotechnology shares in Q2 2026, an estimated $3.03M.
  • Sana Biotechnology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2236 holding.
  • Vanguard Capital Management first reported a position in Sana Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 208 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.